The company’s executive management consists of the Chief Executive Officer, the Chief Financial Officer, the VP Sales and the Chief Technology Officer. The extended operational management group includes nine people.
Sara Thorslund, PhD
Chief Executive Officer
Co-founder and CEO of Gradientech since its start in 2009. Sara Thorslund has received several innovation and entrepreneurship awards as growing Gradientech into an international diagnostics company. Presented as one of today’s role models shaping our future in book publication by Mondial (2020). Holds a MSc in Engineering Biology from Linköping University and a PhD in Material Science and Microstructure Technology from Uppsala University. Author of +10 peer-reviewed scientific publications and inventor of a handful patents.
Education: PhD in Material Science and Microstructure Technology from Uppsala University. Master of Sciece in Engineering Biology from Linköping University.
Previous experience: Co-founder of Gradientech AB 2009. Research in patient-centered microfluidic applications at Uppsala University.
Shareholding: 404 500
Option holding: 94 500
Chief Financial Officer
Urban Adolfsson has a broad background within finance in different roles and organizations including accounting, financial and business analysis, cash and investment planning as well as equity raising. He has held positions as auditor in Ernst & Young, acting CFO / Head of Group Control at PA Resources (Oil & gas), Head of Business control at Envirotainer (Logistics & Supply chain) and CFO / Interim CEO in Encare (Digitalisation of medical science). Urban Adolfsson holds a MSc in Business and Economics from Uppsala University.
Education: Master of Science in Business and Economics from Uppsala University.
Previous experience: Previous positions includes auditor in Ernst & Young, acting CFO / Head of Group Control at PA Resources (Oil & gas), Head of Business control Envirotainer (Logistics & Supply chain) and CFO / Interim CEO in Encare (Digitalisation of medical science).
Shareholding: 1 200
Option holdings: 27 743
Peter Karlberg joined Gradientech in 2022 to build and lead the commercial part of the company. He has more than 20 years of experience from international commercialising of expanding enterprises as well as launching new product lines for larger life science companies. He has been engaged in leading commercial roles in companies such as Life Technologies, Thermo Fisher Scientific, Roche Diagnostics, but also smaller companies such as Fluidigm, Olink, Celsee, and Pyrosequencing. Peter Karlberg holds a BSc in molecular biology from Uppsala University. Peter served as a Board member for Gradientech 2010-2015.
Education: Bachelor of Science in Molecular Biology from Uppsala University.
Previous experience: More than 20 years of experience from international commercialising of expanding enterprises as well as launching new product lines for larger life science companies.
Ongoing assignments: Owner and Chairman of the Board of KÅBE Market development
Shareholding: 17 000
Option holdings: 27 743
Chief Technology Officer
Marcus Berglund joined Gradientech in 2017 and has more than 15 years of experience within system, electronics and SW development. The last 10 years he has been engaged in leading development roles such as team lead, project manager and consultant manager. Passionate about technology and development in life changing applications with direct experience from projects within Life Science, Automotive and Industrial development. Marcus Berglund holds a MSc in Electronics Design Engineering from Linköping University.
Education: Master of Science in Electronics Design from Linköping University.
Previous experience: More than 15 years of experience in industrial system, electronics and software development. Project management roles at companies such as Electroengine, Kontigo Care and BlueAir via Prevas AB. Project manager at Gradientech as a consultant since 2017.
Shareholding: 2 438
Option holdings: 25 986
Regulatory Affairs & Quality Assurance Manager
Anna-Lisa Tiensuu has worked in the life science sector for more than 20 years, the last 15+ years focusing on global medical device regulatory affairs and quality management. Anna-Lisa Tiensuu holds a MSc in Engineering Physics and a Licentiate of Engineering degree in Material Science from Uppsala University.
Education: Master of Science in Engineering Physics and Licentiate of Engineering Degree in Material Science from Uppsala University.
Previous experience: Previous positions include managing positions within Regulatory Affairs, Quality and Design Assurance at for example Doxa Dental, Phadia/ Thermo Fisher (Clinical diagnostics within allergy, asthma and autoimmune diseases), StJude and former Radi Medical Systems (Medical devices for intravascular monitoring and hemostasis).
Shareholding: 1 000
Option holdings: 26 933
Marketing & Communication Manager
Ann-Sofie Andersson joined Gradientech in 2013 and has over 30 years of experience within the Life Science Sector from companies such as Pharmacia Diagnostics (today Thermo Fisher Scientific), Anamar and Mercodia. Previous positions include roles as Product Manager, International Marketing, Sales and Project Management. Ann-Sofie Andersson has also broad experience from business development, quality assurance and distributor environment.
Education: Marketing and university studies in cell biology and immunology from Uppsala University.
Previous experience: Over 30 years of experience from companies in the Life Science sector such as Pharmacia Diagnostics, Anamar and Mercodia. Previous positions include roles as product manager, as well as in international marketing, sales and project management. Broad experience in business development, quality assurance and distributor management.
Option holding: 37,749
Christer Malmberg, PhD
Christer Malmberg has solid experience from clinical and diagnostic microbiology research, investigating methods for early detection of phenotypic effects of antibiotics. Joined Gradientech in 2014 as project leader for the instrument development, and was in 2017 additionally awarded a PhD research grant from Uppsala Antibiotic Centre focusing on the clinical performance evaluation of Gradientech's microfluidic platform for rapid AST. Christer Malmberg holds a PhD in Medical Science and MSc in Molecular Biotechnology Engineering from Uppsala University.
Education: PhD in Medical Science and MSc in Molecular Biotechnology from Uppsala University.
Previous experience: Research background in clinical microbiology and antibiotic resistance. Since 2014 project manager for instrument development and data analysis within Gradientech’s development project within AST diagnostics.
Option holding: 35, 316
Martin Karlsson, PhD
Production & Supply Manager
Martin Karlsson joined Gradientech in 2021 and has industry experience from the medical device and pharmaceutical sector, with positions within quality and development functions since 2012. Focusing on processes for efficiency and quality he believes is a key for developing successful production and supply operations within Gradientech. Martin Karlsson holds a PhD in physical chemistry from Uppsala University and a MSc in analytical chemistry from Linköping University.
Education: PhD in physical chemistry from Uppsala University. MSc in analytical chemistry from Linköping University.
Previous experience: Positions within quality and development functions since 2012.
Other ongoing assignment: –
Option holding: 27,743
Cecilia Johansson, PhD
Head of Microbiology
Cecilia Johansson has more than 20 years of research experience working with clinically relevant bacteria and viruses including solid experience within a range of microbiology and molecular biology analysis methods. Cecilia Johansson holds a MSc in Biology and a PhD in Medical Virology from Uppsala University and is author of +15 peer-reviewed scientific publications. Joined Gradientech in 2019, managing the team of microbiologists and project leading the microbiology activities and facilities.
Education: PhD in medical virology and Master in Science in biology from Uppsala University.
Previous experience: More than 20 years of research experience and work with clinically relevant bacteria and viruses, many years of expertise in microbiological and molecular biological analysis methods.
Option holding: 27 744
Next-generation antimicrobial susceptibility testingTake a look at our E-book